Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease

NCT ID: NCT01791686

Last Updated: 2014-03-07

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 1 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-01-31
• Study Completion Date: 2014-03-31

Brief Summary

This study is evaluating the study drug (CDX-1135) in patients with dense deposit disease (DDD). The objective is to evaluate the safety and activity of repeated doses of CDX-1135 in pediatric and adult patients with DDD. After screening, eligible patients will be entered into the Induction Period. The Induction Period is up to 4 weeks. Following normalization of complement activity, patients will enter into the Maintenance Period.The total treatment duration is up to 26 weeks.

Conditions

Dense Deposit Disease; Membranoproliferative Glomerulonephritis Type II; C3 Glomerulonephritis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dense Deposit Disease

► Induction Period

Patients will receive CDX-1135 as an IV infusion twice weekly (Mon-Thur or Tues-Fri). There will be two doses of 5 mg/kg, with intrapatient dose-escalation in 5 mg/kg increments up to a maximum dose of 30 mg/kg. This period may last up to 8 weeks.

► Maintenance Period

The starting dose for CDX-1135 Maintenance will be the same dose level as the last dose during the Induction Period; however, the Maintenance Period allows for dose decrease to 2 mg/kg, which is lower than the starting dose in the Induction Period.

Patients will receive CDX-1135 as an IV infusion twice weekly (Mon-Thur or Tues-Fri) for up to a total of 26 weeks.

Group Type: EXPERIMENTAL

CDX-1135

Intervention Type: DRUG

Interventions

CDX-1135

Intervention Type: DRUG

Other Intervention Names

TP10; sCR1

Eligibility Criteria

Inclusion Criteria

Among other criteria, patients must be

1. Patient and/or parent/legal guardian (as appropriate) must give written informed consent

2. Four (4) years of age or older

3. Must have DDD, confirmed by renal biopsy within 6 months of study enrollment (Confirmation by University of Iowa investigators is required). If the patient is post transplant, the repeat renal transplant biopsy must show C3 dominant glomerulonephritis, and the patient must have a history of known DDD in the native kidney

4. Signs of abnormal complement pathway activity

5. Serum creatinine level must be abnormal

6. Screening lab values criteria:

1. Hgb ≥ 9.0 g/dL

2. Platelets ≥ 100,000/mm^3

3. ALT and AST ≤ 3.0 x upper limit of normal

4. C3 serum <50% of the lower limit of normal

5. 24 hour urine protein >1000 mg/day, or urine protein:creatinine ratio >1.0

7. Both male and female patients of childbearing potential enrolled must use adequate birth control during the trial and for 1 month after stopping study drug

8. Willing and able to comply with study procedures, including pre-study vaccinations (meningitis, haemophilus and pneumococci) and agree to a renal biopsy at Week 13 and at the end of the study

9. Any anti-proteinuric medications (eg, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers) must be at a stable dose for 4 weeks prior to first dose of CDX-1135

Exclusion Criteria

Among other criteria, patients must not be

1. Dialysis or a low estimated glomerular filtration rate <30 ml/min/1.73m^2 over a 4-week period prior to Screening

2. Active or untreated systemic bacterial infection

3. Pregnant or lactating

4. Rituximab therapy (unless discontinued with B cell levels and immunoglobulin levels normalized by study entry)

5. Immunosuppressive therapies (except for low dose steroids [≤10 mg per day] given for non-DDD related conditions such as asthma). Exceptions will be made for renal transplant patients, who may receive any appropriate therapies as needed to maintain the transplant (i.e., to prevent rejection)

6. Treatment with any complement inhibitor within 3 months of study entry or any other investigational drug, device, or experimental procedure within 4 weeks prior to enrollment

7. For renal transplant patients only: histology findings of treatable rejection (i.e. that the usual transplant physician would seek to treat). Chronic allograft nephropathy is not exclusionary provided the patient's glomerular filtration rate meets other entry criteria

8. Preexisting condition with an association as a potential cause of DDD (i.e., Monoclonal Gammopathy of Undetermined Significance) or an alternate glomerular disease

9. Cancer except for adequately treated and cured basal or squamous cell skin cancer, curatively treated in situ disease, or other cancer that the patient has been disease-free for ≥ 5 years

10. Myocardial infarction within 1 year of screening, congestive heart failure, arrhythmia persistent on medication at screening or chronic lung disease

11. Known HIV, Hepatitis B or Hepatitis C

12. Any medical or psychological condition that would increase the patient's risk by being in this study or would interfere with interpretation of the study

• Minimum Eligible Age: 4 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Celldex Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Carla Nester, MD, MSA

Role: PRINCIPAL_INVESTIGATOR

University of Iowa

Richard Smith, MD

Role: PRINCIPAL_INVESTIGATOR

University of Iowa

Locations

University of Iowa Hospitals & Clinics

Iowa City, Iowa, United States

Countries

United States

Other Identifiers

CDX1135-01

Identifier Type: -

Identifier Source: org_study_id